Marked therapeutic effect of dimyristoylphosphatidylcholine liposomes on carcinoma mice model in vivo.
Significantly prolonged survival rate was obtained for the first time using carcinoma mice models after the administration of single-component liposomes of dimyristoylphosphatidylcholine (DMPC) without any drug. An increase in lymphocytes under optical microscope was observed without any increase in the neutrophils count, suggesting that the DMPC liposomes might inhibit the tumor growth as well as increase in lymphocytes in vivo.
Ueoka
R
R
Graduate Course of Applied Chemistry, Sojo University Kumamoto, Japan. ueoka@life.sojo-u.ac.jp
Matsumoto
Y
Y
Kanno
A
A
Tsuzaki
K
K
Ichihara
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry / Q000627:therapeutic use*; D004906:Erythrocyte Count; D006801:Humans; D007958:Leukocyte Count; D008081:Liposomes; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010743:Phospholipids / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D016019:Survival Analysis
D000970:Antineoplastic Agents; D008081:Liposomes; D010743:Phospholipids; D004134:Dimyristoylphosphatidylcholine